Meeting
2023 ASCO Genitourinary Cancers Symposium
Immunohistochemical (IHC) subtypes of metastatic bladder cancer (mBC) using GATA3 and CK5/6.
Authors
Ariel Ann Nelson
The Medical College of Wisconsin, Department of Medicine, Division of Hematology and Oncology, Milwaukee, WI
Ariel Ann Nelson , Mariel Molina Nunez , Kathryn A. Bylow , Aniko Szabo , Kenneth Iczkowski , Deepak Kilari
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 557)
DOI
10.1200/JCO.2023.41.6_suppl.557
Abstract #
557
Poster Bd #
M20
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Breakthrough
Differences in the expression heterogeneity of ADC-related markers between primary tumors and metastatic lymph nodes in advanced urothelial cancers.
First Author: Xingliang Tan
Poster
2024 ASCO Genitourinary Cancers Symposium
AI-based morphologic model for prediction of individual patient response to immune checkpoint inhibitors for bladder cancer.
First Author: Monica Nair
Poster
2023 ASCO Genitourinary Cancers Symposium
Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma in England: A retrospective cohort study using data from the National Cancer Registry and treatment and hospital data.
First Author: Prantik Das
Poster
2022 ASCO Annual Meeting
Real-world treatment patterns and outcomes among patients (pts) with second-line (2L) and third-line (3L) metastatic triple-negative breast cancer (mTNBC) in England using the Cancer Analysis System (CAS).
First Author: Lawrence Chang